Acute Myeloid Leukemia (AML) in Remission
Conditions
Brief summary
This phase III trial is conducted to evaluate if azacitidine in combination with venetoclax as maintenance therapy improves relapse-free survival (RFS) for younger adults with favorable-risk acute myeloid leukemia (AML) who remained in first complete remission (CR1) following intensive consolidation.
Interventions
DRUGAzacitidine
Given SC
DRUGVenetoclax
Given PO
OTHERSupportive care
Patients will receive disease monitoring and supportive care for any complication.
Sponsors
The First Affiliated Hospital of Soochow University
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to 64 Years
Healthy volunteers
No
Inclusion criteria
1. Diagnosis of favorable-risk acute myeloid leukemia (AML) according to revised 2017 European LeukemiaNet genetic risk stratification and are not immediate candidates for allogeneic stem cell transplant. 2. Aged 18-64 years. 3. Patients who have received remission induction therapy and 3-4 HiDAC or medium-dose cytarabine-based consolidation and are in their first remission. 4. ECOG performance status of \< or = 3. 5. Adequate organ function as follows: 1. Serum total bilirubin \< or = to 3 X the Upper Limit of Normal (ULN) 2. Aspartate Transaminase and alanine transaminase \< or = to 3 x ULN 3. Ccr（Creatinine Clearance Rate) \> or ＝60 ml/min 4. Left ventricular ejection fraction \> or ＝50% determined by ultrasound. 6. For females of childbearing age, they should have a negative serum or urine pregnancy test within 10 to 14 days of enrolling. 7. For males of childbearing age, they should take effective contraceptive methods throughout the treatment period and up to 30 days after discontinuing treatment. 8. Ability to understand and sign informed consent.
Exclusion criteria
1. Acute promyeloid leukemia. 2. Patients with active central nervous system (CNS) leukemia. 3. Previously diagnosed with myelodysplastic syndrome (MDS) or myeloproliferative neoplasm(MPN) and progressed to AML. 4. Patients with other progressive malignancies. 5. Evidence of other clinically significant uncontrolled condition(s) including, but not limited to uncontrolled and/or active systemic infection (viral, bacterial or fungal). 6. Patients who have participated in other trials within 30 days before signing the informed consent. 7. Females who are pregnant or lactating or intending to become pregnant during the study.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Relapse-free survival (RFS) | From date of complete remission (CR) or complete remission with incomplete count recovery (CRi), to relapse or death from any cause, up to approximately 3 years | RFS is defined as the number of days from CR/CRi to the date of relapse or the date of death from any cause, whichever comes first. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Percentage of Participants Who Achieve Minimal Minimal Residual Disease (MRD) Negative Conversion | Measured From Baseline to approximately 3 years | The MRD conversion rate is defined as the percentage of participants deemed MRD positive (≥ 10\^-3) at study initiation who converted to MRD of \< 10\^-3 in the bone marrow after randomization or initiation of treatment. |
| Complete remission duration (CRd) | From date of CR/CRi to approximately 3 years | CRd is defined as time from CR/CRi until date of confirmed relapse |
| Overall Survival (OS) | Time from treatment to death from any cause, up to approximately 3 years | OS is defined as the number of days from the date of study treatment to the date of death. |
| Event free survival (EFS) | Time from treatment to relapse，withdrawal from study due to adverse event and death from any cause, up to approximately 3 years | EFS is defined as time from the start of study treatment until date of first confirmed relapse, withdrawal from study due to adverse event, or death due to any cause, |
| Incidence of adverse events | Time from treatment to approximately 3 years | The NCI Common Toxicity Criteria (CTCAE 5.0) is used to grade adverse events. |
Countries
China
Contacts
Primary ContactSuning Chen
Outcome results
None listed